Aimmune Therapeutics says the US FDA approves drug to reduce, and potentially eliminate, allergic reactions to peanuts in children aged 4 to 17

The treatment, called AR101 and to be sold under the brand name Palforzia, was designed to gradually reduce sensitivity to peanuts by exposing patients to a highly refined version of peanut flour over the course of several months.

The oral drug will be the first in the market to offer relief from peanut allergy symptoms for those who previously had to avoid all contact with peanuts in any form or risk a reaction requiring emergency treatment with an EpiPen or another epinephrine shot.